BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

BioTech Health X

803 posts

Biotech NewsAcelyrin (SLRN) is Exploding in 2025 – Is SLRN the Hottest Biotech Play Right Now?

  • BioTech Health X
  • July 31, 2025
Acelyrin, Inc. is a biotechnology company headquartered in California that focuses on developing innovative immunology-based therapies to address…
0 Shares
0
0
0
0
0
0
0

Biotech NewsKiniksa Pharmaceuticals (KNSA) is Breaking Out

  • BioTech Health X
  • July 31, 2025
Kiniksa Pharmaceuticals International PLC is a global biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for patients…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAnalysts Are Bullish: Could Aurinia (AUPH) Be the Next Billion-Dollar Biotech Winner?

  • BioTech Health X
  • July 31, 2025
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for the treatment of…
0 Shares
0
0
0
0
0
0
0

Biotech NewsFrom $10 to $23? Why Niagen Bioscience (NAGE) Could Be the Next Big Biotech Success Story

  • BioTech Health X
  • July 28, 2025
Niagen Bioscience Inc. (NASDAQ:NAGE) is a pioneering life sciences company that has become a global leader in the…
0 Shares
0
0
0
0
0
0
0

Biotech NewsWall Street Is Going Crazy Over UroGen Pharma (URGN) – Here’s Why it Could Be a 2025 Winner

  • BioTech Health X
  • July 28, 2025
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty…
0 Shares
0
0
0
0
0
0
0

Biotech NewsCel-Sci (CVM) Could Skyrocket 3,000% – Here’s Why Investors Are Buzzing

  • BioTech Health X
  • July 28, 2025
Cel-Sci Corporation (NYSE:CVM) is gaining renewed attention from both retail and institutional investors as it continues to push…
0 Shares
0
0
0
0
0
0
0

Biotech NewsFDA Decision Incoming! Apellis Pharmaceuticals (APLS) Could Be the Next 10X Biotech Stock!

  • BioTech Health X
  • July 28, 2025
Apellis Pharmaceuticals Inc (NASDAQ:APLS) is a pioneering biotechnology company dedicated to transforming the treatment landscape for patients living…
0 Shares
0
0
0
0
0
0
0

Biotech NewsFrom NeuroBo to MetaVia (MTVA): This Biotech Just Went All-In on Obesity and Liver Disease

  • BioTech Health X
  • July 23, 2025
MetaVia Inc. (NASDAQ:MTVA), formerly NeuroBo Pharmaceuticals, Inc, is a clinical-stage biotechnology company focused on developing next-generation therapies for…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAlterity Therapeutics (ATHE) is One FDA Meeting Away From a Major Breakout

  • BioTech Health X
  • July 23, 2025
Alterity Therapeutics Ltd. (NASDAQ:ATHE) is a clinical-stage biotechnology company headquartered in Melbourne, Australia, focused on developing innovative therapies…
0 Shares
0
0
0
0
0
0
0

Biotech NewsLiminatus Pharma (LIMN) Might Be the Most Disruptive Micro-Cap on NASDAQ

  • BioTech Health X
  • July 23, 2025
Liminatus Pharma Inc. (NASDAQ:LIMN) is a preclinical-stage biopharmaceutical company dedicated to the discovery and development of targeted cancer…
0 Shares
0
0
0
0
0
0
0

Biotech NewsThermo Fisher (TMO) Is Everywhere—And That’s Exactly Why It’s Winning

  • BioTech Health X
  • July 23, 2025
Thermo Fisher Scientific Inc (NYSE:TMO) is a global leader in the scientific and healthcare solutions industry, renowned for…
0 Shares
0
0
0
0
0
0
0

Biotech NewsKrystal Biotech (KRYS) Just Changed Gene Therapy Forever—Smart Investors Are Paying Attention

  • BioTech Health X
  • July 22, 2025
Krystal Biotech, Inc. (NASDAQ: KRYS) is a cutting-edge biotechnology company pioneering the development of redosable genetic medicines aimed…
0 Shares
0
0
0
0
0
0
0

Biotech NewsSeres Therapeutics (MCRB): The $100M Microbiome Gem Flying Under Wall Street’s Radar

  • BioTech Health X
  • July 22, 2025
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a pioneering biotechnology company at the forefront of developing microbiome therapeutics—a groundbreaking class…
0 Shares
0
0
0
0
0
0
0

Biotech NewsTelesurgery Is Here—and Intuitive Surgical (ISRG) Owns It

  • BioTech Health X
  • July 22, 2025
Intuitive Surgical, Inc., founded in 1995 and headquartered in Sunnyvale, California, is a trailblazer in the field of…
0 Shares
0
0
0
0
0
0
0

Biotech NewsMedpace (MEDP) Just Soared 50%—Is This the Most Underrated Biotech Play of 2025?

  • BioTech Health X
  • July 22, 2025
Medpace Holdings Inc. (NASDAQ:MEDP) is a leading global contract research organization (CRO) that partners with biopharmaceutical, biotechnology, and…
0 Shares
0
0
0
0
0
0
0

Biotech NewsTransMedics (TMDX) Could Be the Tesla of Transplants — Here’s Why Investors Are Paying Attention

  • BioTech Health X
  • July 21, 2025
TransMedics Group, Inc. (NASDAQ:TMDX) is a pioneering medical technology company that is fundamentally transforming the landscape of organ…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAstera Labs (ALAB) is Down from Highs — But Here’s Why It’s About to Rebound Hard

  • BioTech Health X
  • July 21, 2025
Astera Labs Inc. (NASDAQ:ALAB) is a rapidly emerging leader in intelligent connectivity solutions designed to address the unique…
0 Shares
0
0
0
0
0
0
0

Biotech NewsWall Street Sees 75% Upside: Is Replimune (REPL) the Best Biotech Stock to Buy Now?

  • BioTech Health X
  • July 21, 2025
Replimune Group, Inc. (NASDAQ:REPL) is a biotechnology company pioneering a transformative class of cancer therapeutics based on its…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
  • Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
  • Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
  • Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
  • The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • February 13, 2026
    PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
    • February 13, 2026
    Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
    • February 13, 2026
    Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
    • February 13, 2026
    Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
    • February 13, 2026
    The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Posts
  • Verastem (VSTM) Isn’t “Small-Cap Roulette” Anymore—It’s a Commercial Oncology Ramp With a 2026 Twist
    • February 13, 2026
  • The Market Cap Is Small, the Idea Is Huge: Can Allogene (ALLO) Make CAR-T as Easy as Ordering a Drug?
    • February 13, 2026
  • 44% Real-World Response? Iovance (IOVA) Just Made “Off-the-Bench” Data the New Headline
    • February 13, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (787)
  • Uncategorized (2)
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top